Orca-T integrates HSPCs for reconstitution, highly purified Tregs for GVHD suppression, and Tcons to accelerate immune recovery and preserve graft-versus-leukemia activity via a matched-donor, patient ...

FDA authorized Tregzi for adults with acute leukemia, MDS, and other hematologic malignancies receiving closely matched donor ...

Add Yahoo as a preferred source to see more of our stories on Google. A Flint woman is believed to be the first in the world with leukemia to successfully undergo a transplant using stem cells from ...

The FDA has approved an allogeneic regulatory T cell immunotherapy for use in matched-donor hematopoietic stem cell transplantation in patients with blood cancers, to improve survival for chronic ...

The study reported 10-year survival rates of 81.3% for ALL and 76.2% for AML post-HCT. Relapse and cGVHD were the primary causes of late mortality, with relapse contributing to 33.9% of ALL and 44.9% ...

Bone marrow transplants can be life-saving for patients suffering from certain types of cancer, blood disorders and other diseases — but for many patients, finding a match can take months or years.

For patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplantation, posttransplant cyclophosphamide (PTCy) graft-versus-host-disease (GVHD) prophylaxis yields comparable ...

Initial fatigue was attributed to parenting demands before marked leukocytosis prompted an ER leukemia diagnosis, reinforcing the value of reassessment and second-opinion confirmation when symptoms ...

As part of consolidation therapy, patients may receive allogenic hematopoietic stem cell transplantation (HCT). HCT involves the replacement of a patient's normal source of bone marrow cells by ...